3-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / October 20, 2017 / Khang & Khang LLP (the ”Firm”) announces a securities class action lawsuit against Teva Pharmaceutical Industries Limited (”Teva” or the”Company”) (NYSE: TEVA). Investors who purchased or otherwise acquired Teva shares from November 15, 2016 through August 2, 2017, inclusive (the ”Class Period”), are encouraged to contact the Firm by October 23, 2017, the lead plaintiff
motion deadline.

If you purchased Teva shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

The Complaint alleges that throughout the Class Period, Teva issued materially false and/or misleading statements, and/or failed to disclose, that the poor performance of its U.S. generics business resulted in the Company recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva’s dividend by 75%. When this information was released, shares of Teva fell in value materially, which caused investors harm according to the lawsuit.

If you want to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 478398